Literature DB >> 17964977

Malignant meningiomas: a retrospective study of 22 cases.

Yuguang Liu1, Meng Liu, Feng Li, Chengyuan Wu, Shugan Zhu.   

Abstract

Malignant (anaplastic) meningioma constitutes a rare subset of meningioma. The aim of the study was to study clinical features and management of malignant meningiomas. Twenty-two patients with malignant meningiomas were surgically treated in our department between January 1986 and January 2005 in Qilu hospital, and we reviewed each patient's clinical records, radiological findings, operative reports, and pathological examinations. Simpson grade I resection was achieved in 16 cases and grade II resection in 6 cases. Postoperative radiotherapy was performed in all patients. No death occurred during the perioperative period in this series. The follow-up period ranged from six months to ten years. Overall 5-year survival and recurrence-free survival estimates were 36.4 and 27.3%, respectively. 16 patients with Simpson Grade I resection had longer median survival times than 6 patients with Simpson Grade II resection (70 months compared with 10 months, p = 0.0001). Only tumor location (p = 0.016) and Simpson grade of surgical resection (p = 0.002) had an impact on outcome according to a Cox regression analysis. Surgical resection and adjuvant radiotherapy are the main treatments for malignant meningiomas, and the degree of tumor removal is the leading factor determining postoperative recurrence and survival.

Entities:  

Mesh:

Year:  2007        PMID: 17964977

Source DB:  PubMed          Journal:  Bull Cancer        ISSN: 0007-4551            Impact factor:   1.276


  2 in total

1.  Anatomic location is a risk factor for atypical and malignant meningiomas.

Authors:  Ari J Kane; Michael E Sughrue; Martin J Rutkowski; Gopal Shangari; Shanna Fang; Michael W McDermott; Mitchel S Berger; Andrew T Parsa
Journal:  Cancer       Date:  2010-11-08       Impact factor: 6.860

2.  Extensive growth of an anaplastic meningioma.

Authors:  Hajrullah Ahmeti; Homajoun Maslehaty; Athanasios K Petridis; Alexandros Doukas; Mehran Mahvash; Harald Barth; H M Mehdorn
Journal:  Case Rep Neurol Med       Date:  2013-10-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.